porcin
reproduct
respiratori
syndrom
viru
prrsv
econom
import
pathogen
viru
swine
product
current
vaccin
prrsv
induc
steril
immun
viru
evolv
rapid
rate
frequent
appear
new
strain
studi
screen
librari
highli
purifi
natur
product
compound
identifi
specif
inhibitor
prrsv
replic
cycl
observ
show
mani
inhibitori
compound
identifi
activ
cellular
ion
transport
mechan
identifi
first
time
four
compound
inhibit
prrsv
replic
cycl
micro
molar
concentr
less
name
ouabain
bufalin
valinomycin
identifi
compound
inhibit
prrsv
replic
concentr
lm
studi
provid
basi
develop
pharmacolog
agent
inhibit
prrsv
replic
porcin
reproduct
respiratori
syndrom
viru
prrsv
econom
import
pathogen
viru
swine
product
current
vaccin
prrsv
induc
steril
immun
viru
evolv
rapid
rate
frequent
appear
new
strain
studi
screen
librari
highli
purifi
natur
product
compound
identifi
specif
inhibitor
prrsv
replic
cycl
observ
show
mani
inhibitori
compound
identifi
activ
cellular
ion
transport
mechan
identifi
first
time
four
compound
inhibit
prrsv
replic
cycl
micro
molar
concentr
less
name
ouabain
bufalin
valinomycin
identifi
compound
inhibit
prrsv
replic
concentr
lm
studi
provid
basi
develop
pharmacolog
agent
inhibit
prrsv
replic
elsevi
bv
right
reserv
porcin
reproduct
respiratori
syndrom
viru
prrsv
import
pathogen
porcin
speci
caus
estim
annual
loss
million
dollar
swine
product
industri
unit
state
alon
http
nationalhogfarmercom
august
emerg
prrsv
pathogen
first
observ
current
global
epizoot
murtaugh
genzow
viru
belong
order
nidoviral
famili
arterivirida
character
posit
strand
rna
genom
approxim
kb
kilobas
envelop
prrsv
viral
genom
rna
cap
polyadenyl
viru
classifi
two
major
strain
type
european
type
ii
north
american
shi
et
al
structur
protein
viru
encod
distal
third
viral
genom
transcrib
subgenom
mrna
nonstructur
protein
take
proxim
two
third
viral
genom
synthes
shorter
longer
polyprotein
process
smaller
protein
consist
varieti
enzym
proteas
rna
polymeras
rna
helicas
nonstructur
protein
shown
suppress
induct
host
type
interferon
gene
cytokin
beura
et
al
patel
et
al
prrsv
estim
high
rate
evolut
substitut
per
nucleotid
site
per
year
new
strain
frequent
appear
field
song
et
al
current
avail
inactiv
modifi
live
vaccin
inadequ
erad
viru
provid
complet
immun
infect
murtaugh
genzow
modifi
live
vaccin
prrsv
strain
also
character
shed
viru
vaccin
anim
often
revert
virul
strain
murtaugh
genzow
storgaard
et
al
sinc
global
prrsv
epizoot
pig
complet
amen
immunolog
intervent
pharmacolog
intervent
might
valuabl
altern
addit
control
measur
prrsv
past
studi
cell
cultur
model
reveal
compound
display
antivir
activ
see
tabl
gener
natur
compound
constitut
major
sourc
effect
pharmacolog
agent
includ
artemisinin
anti
tumor
alkaloid
salicyl
opiat
etc
mishra
tiwari
therefor
evalu
commerci
avail
librari
natur
product
librari
enzo
life
scienc
purifi
natur
compound
activ
prrsv
infect
replic
end
establish
highthroughput
screen
method
immunofluoresc
assay
ifa
base
highthroughput
screen
platform
well
format
detect
viral
replic
establish
util
cell
permiss
prrsv
infect
viral
protein
detect
use
highli
speci
fic
monoclon
antibodi
nucleocapsid
protein
prrsv
clone
inhous
produc
empir
ical
optim
assay
perform
seed
cell
per
well
infect
multipl
infect
moi
time
seed
antivir
effect
evalu
h
postinfect
fix
cell
paraformaldehyd
includ
mockinfect
cell
prrsvinfect
cell
addit
lm
mycophenol
acid
mpa
de
novo
purin
synthesi
inhibitor
siever
et
al
neg
posit
control
respect
viru
inhibit
replic
list
compound
found
inhibit
prrsv
replic
lm
concentr
less
observ
ifa
signal
intens
without
decreas
dapi
intens
treat
cell
less
con
control
inhibitor
mpa
cepharanthin
alkaloid
antivir
activ
sar
cov
antiinflammatori
inhibit
lipooxygenas
baba
et
al
zhang
et
al
coumermycin
novobiocin
relat
antibiot
antivir
activ
et
al
cryptotanshinon
herb
deriv
tanshinon
block
signal
transduc
activ
transcript
dimer
inhibit
cytokin
product
immun
cell
kang
et
al
shin
et
al
cyclopiazon
acid
fungal
metabolit
act
endoplasm
reticulum
resid
ca
atpas
mediat
activ
nfkb
key
compon
immun
cell
signal
xia
et
al
phorbol
ester
activ
pkcb
mimic
ifn
mediat
signal
saraiva
et
al
hydrastin
dban
alkaloid
antiinflammatori
agent
inhibit
cytochrom
mediat
oxid
raner
et
al
ouabain
cardiac
glycosid
antivir
activ
su
et
al
immunofluoresc
assay
primari
mous
monoclon
antibodi
hybridoma
supernat
use
undilut
secondari
donkey
antimous
immunoglobulin
antibodi
label
alexa
fluor
stock
lgll
use
dilut
pbstween
primari
secondari
antibodi
stock
bulk
quantiti
aliquot
stock
valid
assay
highli
reliabl
util
assay
compound
natur
product
librari
screen
abil
inhibit
viral
entri
orand
replic
ad
lm
compound
dmso
final
concentr
cell
plu
viru
mixtur
time
seed
mockinfect
cell
infect
cell
infect
cell
lm
mpa
infect
cell
dmso
use
control
compound
caus
decreas
dapi
intens
treat
cell
less
infect
cell
dmso
consid
toxic
cell
exclud
analysi
screen
repeat
twice
identifi
compound
inhibit
viru
replic
less
lm
concentr
observ
ifa
signal
intens
without
advers
affect
host
cell
tabl
compound
librari
use
screen
compris
sever
class
natur
compound
glycosid
terpenoid
coumarin
isoflavon
peptolid
alkaloid
flavon
macrolid
etc
compound
belong
glycosid
known
action
cardiac
system
cardioact
steroid
found
higher
frequenc
inhibit
viral
replic
assay
identifi
inhibitor
five
glycosid
two
cardioact
steroid
compound
share
similar
mode
action
ion
channel
cell
whether
compound
act
cellular
mechan
indirectli
affect
viru
act
directli
viral
compon
mechan
determin
like
viral
target
compound
could
viral
porin
prrsv
envelop
form
multimer
small
envelop
protein
lee
yoo
amantadin
known
block
ion
channel
influenza
also
block
prrsv
porin
lee
yoo
compound
inhibit
prrsv
includ
fungal
metabolit
flavon
subsequ
select
ten
compound
tabl
consid
presenc
known
relat
pharmacolog
compound
biolog
effect
compound
cycloheximid
dicoumarol
harmalin
select
panel
due
known
undesir
biolog
activ
profil
toxic
effect
select
ten
compound
cell
analyz
use
alamar
blue
test
invitrogen
follow
manufactur
instruct
alamar
blue
fluoresc
infect
cell
treat
compound
less
untreat
infect
cell
correl
dapi
fluoresc
intens
estim
previous
data
shown
inhibitori
effect
compound
evalu
use
signal
intens
ifa
assay
describ
earlier
lm
concentr
compound
tabl
ad
compound
viru
cell
time
seed
treatment
perform
triplic
experi
perform
twice
ten
compound
inhibit
viru
replic
lm
concentr
four
compound
inhibitori
lm
submicro
molar
concentr
dppa
ouabain
valinomycin
bufalin
repres
imag
infect
shown
fig
interestingli
dppa
known
activ
pkcb
stimul
interferon
signal
ouabain
bufalin
known
act
cardiac
system
affect
ion
channel
bufalin
perturb
signal
mediat
valinomycin
dodecadepsipeptid
antibiot
potassium
ionophor
previou
studi
shown
valinomycin
potent
antivir
activ
sever
acut
respiratori
syndrom
corona
viru
sar
cov
anoth
import
nidoviru
wu
et
al
estim
inhibitori
concentr
ic
inhibit
viral
replic
four
compound
describ
earlier
wu
et
al
ic
valu
deriv
curv
fit
mean
percent
infect
cell
triplic
observ
ifa
lm
concentr
inhibitor
three
independ
experi
ic
well
lm
tabl
four
compound
next
evalu
four
compound
act
bind
entri
step
viru
replic
process
cell
incub
compound
lm
h
prior
addit
viru
moi
subsequ
cell
incub
h
cell
wash
thrice
phosphat
buffer
salin
pb
cell
incub
fresh
media
fix
h
result
show
identifi
four
compound
block
bind
entri
viru
act
subsequ
replic
process
next
cell
infect
viru
moi
incub
compound
lm
h
post
infect
hpi
fix
hpi
ifa
signal
quantif
result
tabl
show
viru
replic
almost
complet
inhibit
four
compound
ad
hpi
howev
ad
hpi
dppa
decreas
viral
signal
three
compound
almost
complet
inhibit
signal
result
show
dppa
inhibit
viru
replic
act
earli
event
viruscel
interact
dppa
known
mimic
cellular
interferon
signal
saraiva
et
al
possibl
act
augment
interferon
mediat
viru
suppress
three
compound
known
act
ion
channel
could
differ
mode
action
compound
inhibitori
even
ad
later
stage
infect
could
better
valu
vivo
inhibit
viru
detail
analysi
need
perform
identifi
exact
mode
action
next
inhibitori
activ
compound
test
rapid
cytopath
effect
cpe
inhibit
assay
adapt
cotarelo
et
al
cell
infect
prr
viru
moi
without
four
compound
lm
concentr
examin
cpe
h
post
infect
untreat
infect
cell
show
extens
cpe
hpi
lm
concentr
four
compound
complet
inhibit
observ
cpe
hpi
howev
lm
concentr
dppa
show
mild
cpe
cpe
inhibit
assay
show
compound
effect
inhibit
viru
induc
cellular
patholog
apart
four
compound
compound
origin
identifi
inhibit
prrsv
lm
concentr
analog
compound
could
better
profil
activ
cell
cultur
model
prrsv
replic
vivo
studi
howev
prrsv
infect
could
success
model
laboratori
anim
vivo
studi
perform
pig
piglet
consid
rapid
evolut
rate
prrsv
murtaugh
genzow
song
et
al
erad
viru
achiev
immunolog
intervent
trend
observ
field
far
therefor
therapeut
intervent
pharmacolog
agent
inhibit
viru
replic
could
repres
valuabl
altern
addit
tool
prrsv
latter
combin
immunolog
pharmacolog
intervent
could
decreas
risk
emerg
resist
strain
well
conclus
identifi
sever
natur
compound
display
potent
antivir
activ
provid
basi
research
pharmacolog
agent
prrsv
